Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC).
The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and
safety of lenvatinib as a preoperative conversion therapy in patients with potentially
resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion
treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in
patients with potential resectable HCC and improve the long term survival.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborators:
Anhui Provincial Hospital Tongji Hospital West China Hospital